132646-45-8

Basic information

• Product Name: 2,4-Oxazolidinedione,5-[[2-[(5-methyl-2- phenyl-4-oxazolyl)methyl]-5-benzofuranyl]- methyl]-
• CAS NO: 132646-45-8
• Molecular Weight: 402.406
• Mol File: 132646-45-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2,4-Oxazolidinedione,5-[[2-[(5-methyl-2- phenyl-4-oxazolyl)methyl]-5-benzofuranyl]- methyl]- (CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Oxazolidinedione,5-[[2-[(5-methyl-2- phenyl-4-oxazolyl)methyl]-5-benzofuranyl]- methyl]- (132646-45-8)
• EPA Substance Registry System: 2,4-Oxazolidinedione,5-[[2-[(5-methyl-2- phenyl-4-oxazolyl)methyl]-5-benzofuranyl]- methyl]- (132646-45-8)

Safety Data

• Hazardous Substances Data: 132646-45-8(Hazardous Substances Data)

Upstream product

• 132646-44-7 5-<2-<<(5-methyl-2-phenyl-4-oxazolyl)methyl>-5-benzofuranyl>methylidene>-2,4-oxazolidinedione 
• 132646-43-6 5-<2-<<(5-methyl-2-phenyl-4-oxazolyl)methyl>-5-benzofuranyl>methylidene>-2-thio-2,4-oxazolidinedione 
• 132646-33-4 2-<(5-methyl-2-phenyl-4-oxazolyl)methyl>benzofuran-5-carbonitrile 
• 132672-20-9 5-bromo-α-(5-methyl-2-phenyloxazol-4-yl)-2-benzofuranmethanol 
• 132646-31-2 (5-bromo-2-benzofuranyl)(5-methyl-2-phenyl-4-oxazolyl)methanone 
• 132646-34-5 2-(5-methyl-2-phenyl-4-oxazolyl)methyl-5-benzofurancarboxaldehyde 
• 132646-32-3 2-[(2-Phenyl-5-methyloxazol-4-yl)methyl]-5-bromobenzofuran 
• 1761-61-1 5-bromosalicyclaldehyde 
• 103788-62-1 4-bromoacetyl-5-methyl-2-phenyl-oxazole 

Relevant articles and documents

METHOD OF INHIBITING ANGIOGENESIS

Angiogenesis is inhibited and the growth of tumors is treated by administering an effective amount of a PPAR gamma ligand/agonist, optionally with an RXR receptor ligand.

Use of troglitazone and related compounds for the treatment of the climacteric symptoms

The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPARγ). Troglitazone and related compounds can therefore be used to prevent excessive uterine bleeding during. Further, enhanced translocation of this orphan nuclear receptor into the nucleus of cells will block transcription in rapidly proliferating cancer cells that express PPARγ, resulting in loss of cell viability.

Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus

Novel methods of using thiazolidinone derivatives and related antihyperglycemic agents to treat populations experiencing impaired glucose intolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus (NIDDM) and complications arising therefrom are disclosed.